Overview

“A Phase 3, Open-Label, Multicenter, Randomized Study of Raludotatug Deruxtecan (MK-5909, R-DXd) With or Without Bevacizumab Versus Standard-of-Care Platinum-Based Doublet Chemotherapy With or Without Bevacizumab in Participants With Advanced Platinum-Sensitive High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer who Have Progressed During First-Line PARPi Maintenance (ENGOT-ov107 / GOG-3142 / REJOICE-Ovarian05)”

Researchers are studying whether an investigational treatment called raludotatug deruxtecan (R-DXd), with or without bevacizumab, may work better than standard platinum-based chemotherapy for people with recurrent ovarian, primary peritoneal, or fallopian tube cancer that has progressed during PARP inhibitor maintenance treatment. Participants will be randomly assigned to receive either the investigational treatment or standard treatment. Researchers will compare how long the cancer remains controlled, overall survival, treatment response, side effects, and quality of life.